Molecular Partners Ag (MOLN) Common Equity (2020 - 2026)

Molecular Partners Ag (MOLN) has reported Common Equity for 7 consecutive years, with $87413.5 the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 38.69% year-over-year to $87413.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87413.5 (down 38.69% YoY) and the FY2025 annual result came in at $100511.5, down 37.83% from the prior year.
• Common Equity slipped to $87413.5 in Q1 2026 per MOLN's latest filing, from $100511.5 in the prior quarter.
• Over the last five years, Common Equity for MOLN reached as high as $276.1 million in Q2 2022 and fell as low as $87413.5 in Q1 2026.
• A 5-year average of $40.0 million and a median of $198898.0 in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 109.8% — and 2025, when it sank 99.93%.
• Year by year, Common Equity stood at $244107.5 in 2022, then slipped by 18.52% to $198898.0 in 2023, then slipped by 18.71% to $161680.6 in 2024, then tumbled by 37.83% to $100511.5 in 2025, then declined by 13.03% to $87413.5 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $87413.5, $100511.5, and $119421.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.